Latest news with #VernalKeratoconjunctivitisPipeline

Globe and Mail

Vernal Keratoconjunctivitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight's, 'Vernal Keratoconjunctivitis Pipeline Insight 2025' report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Vernal Keratoconjunctivitis pipeline landscape. It covers the Vernal Keratoconjunctivitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Vernal Keratoconjunctivitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Vernal Keratoconjunctivitis Pipeline. Dive into DelveInsight's comprehensive report today! @ Vernal Keratoconjunctivitis Pipeline Outlook Key Takeaways from the Vernal Keratoconjunctivitis Pipeline Report DelveInsight's Vernal Keratoconjunctivitis pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Vernal Keratoconjunctivitis treatment. The leading Vernal Keratoconjunctivitis Companies such as iCo Therapeutics, Vanda Pharmaceuticals, Sylentis, Allakos and others. Promising Vernal Keratoconjunctivitis Pipeline Therapies such as Cyclosporine A, Dexamethasone, FK506 and others. Stay ahead with the most recent pipeline outlook for Vernal Keratoconjunctivitis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Vernal Keratoconjunctivitis Treatment Drugs Vernal Keratoconjunctivitis Emerging Drugs Profile iCo-008: iCo Therapeutics Bertilimumab is a fully human monoclonal antibody with specificity for human eotaxin-1 and inhibits its function. Favourable results from pre-clinical assessments resulted in three clinical studies of bertilimumab conducted in EU (a total of 126 patients – healthy individuals, patients with a history of seasonal allergic rhinitis and individuals with a history of seasonal allergic conjunctivitis) provided evidence of good safety and tolerability of bertilimumab when administered by the intravenous (IV) or intranasal route as well as topical application to the eye. A Phase II clinical trial for patients with vernal keratoconjunctivitis and/or atopic keratoconjunctivitis (involving cornea and conjunctiva) is in preparation. The Vernal Keratoconjunctivitis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Vernal Keratoconjunctivitis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vernal Keratoconjunctivitis Treatment. Vernal Keratoconjunctivitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Vernal Keratoconjunctivitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vernal Keratoconjunctivitis market Explore groundbreaking therapies and clinical trials in the Vernal Keratoconjunctivitis Pipeline. Access DelveInsight's detailed report now! @ New Vernal Keratoconjunctivitis Drugs Vernal Keratoconjunctivitis Companies iCo Therapeutics, Vanda Pharmaceuticals, Sylentis, Allakos and others. Vernal Keratoconjunctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Molecule Type Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Unveil the future of Vernal Keratoconjunctivitis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Vernal Keratoconjunctivitis Market Drivers and Barriers Scope of the Vernal Keratoconjunctivitis Pipeline Report Coverage- Global Vernal Keratoconjunctivitis Companies- iCo Therapeutics, Vanda Pharmaceuticals, Sylentis, Allakos and others. Vernal Keratoconjunctivitis Pipeline Therapies- Cyclosporine A, Dexamethasone, FK506 and others. Vernal Keratoconjunctivitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Vernal Keratoconjunctivitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Vernal Keratoconjunctivitis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Vernal Keratoconjunctivitis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Vernal Keratoconjunctivitis: Overview Pipeline Therapeutics Therapeutic Assessment Late Stage Products (Phase III) Drug Name: Company Name Drug profiles in the detailed report….. Mid Stage Products (Phase II) Co-008: iCo Therapeutics Drug profiles in the detailed report….. Early stage products (Phase I) AK002: Allakos Drug profiles in the detailed report….. Inactive Products Vernal Keratoconjunctivitis Key Companies Vernal Keratoconjunctivitis Key Products Vernal Keratoconjunctivitis- Unmet Needs Vernal Keratoconjunctivitis- Market Drivers and Barriers Vernal Keratoconjunctivitis- Future Perspectives and Conclusion Vernal Keratoconjunctivitis Analyst Views Vernal Keratoconjunctivitis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: